Search
Flibanserin
go.drugbank.com/drugs/DB04908ApprovedInvestigationalIn December of 2025 the FDA expanded the age of the indication to include postmenopausal women, a first for the FDA and sexual health in that age group. [L54893] … In February of 2018 Flibanserin was approved by Health Canada under the brand name Addyi for a similar indication as approved by the FDA.
Nafarelin
go.drugbank.com/drugs/DB00666ApprovedInvestigationalNafarelin is a potent synthetic agonist of gonadotropin-releasing hormone with 3-(2-naphthyl)-D-alanine substitution at residue 6. … Nafarelin has been used in the treatments of central precocious puberty and endometriosis.
Melphalan flufenamide
go.drugbank.com/drugs/DB16627ApprovedWithdrawnIt has since been withdrawn from the market in the wake of the phase 3 OCEAN trial which showed a decrease in overall survival in comparison to standard treatment with [pomalidomide] and [dexamethasone … [A230123] The increased potency makes melphalan flufenamide a treatment option for patients with relapsed or refractory multiple myeloma who have attempted at least 4 lines of therapy already.
Drospirenone
go.drugbank.com/drugs/DB01395ApprovedInvestigationalDrospirenone is a synthetic progestin commonly found in the popular oral contraceptive, Yaz in combination with [Ethinyl estradiol]. … [A182543,A182552] In 2012, however, a safety statement by the FDA concluded that the increase in the risk of thromboembolism resulting from the use of drospirenone remains unclear, as studies regarding
Mixtures: LÍA, Lo-ZumandimineTrametinib
go.drugbank.com/drugs/DB08911ApprovedInvestigational[L45583] Trametinib is currently approved to treat a variety of cancers with BRAF mutations, such as non-small cell lung cancer and thyroid cancer, as monotherapy or in combination with [dabrafenib], a … [A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexDihydrocodeine
go.drugbank.com/drugs/DB01551ApprovedIllicitIt is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis … It was marketed in 1911.
Mixtures: Duohist DH, EndaCof DHInternational brands: DF-118 ForteSulisobenzone
go.drugbank.com/drugs/DB11185ApprovedAs a group, benzophenones may be used to delay photodegradation or extend shelf life in toiletries and plastic surface coatings [L2671]. … Sulisobenzone is approved by the FDA in concentrations of up to 10% and in Canada, is approved by Health Canada at the same concentrations [F38].
International brands: Uvinul D 5030Mixtures: 3-IN-1 Active Moisturizer, Rayito de SolPibrentasvir
go.drugbank.com/drugs/DB13878ApprovedInvestigationalThese resistance-associated amino acid substitutions included Q30D/deletion, Y93D/H/N or H58D +Y93H in genotype 1a replicons, F28S + M31I or P29S + K30G in genotype 2a replicons, and Y93H in genotype 3a … Individual NS5A amino acid substitutions that reduced susceptibility to pibrentasvir include M28G or Q30D in a genotype 1a replicon and P32-deletion in a genotype 1b replicon [L940].
Idursulfase
go.drugbank.com/drugs/DB01271ApprovedInvestigationalIdursulfase is a purified form of human iduronate-2-sulfatase, a lysosomal enzyme. Idursulfase is produced by recombinant DNA technology in a human cell line. … Idursulfase is a 525-amino acid glycoprotein with a molecular weight of approximately 76 kilodaltons.
Synonyms: Alpha-L-iduronate sulfate sulfataseRipretinib
go.drugbank.com/drugs/DB14840ApprovedInvestigational[L13769] It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors.[L13778] … Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]